Adrienne H. Long

3.5k total citations · 1 hit paper
13 papers, 1.9k citations indexed

About

Adrienne H. Long is a scholar working on Oncology, Immunology and Neurology. According to data from OpenAlex, Adrienne H. Long has authored 13 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Immunology and 4 papers in Neurology. Recurrent topics in Adrienne H. Long's work include CAR-T cell therapy research (8 papers), Neuroblastoma Research and Treatments (4 papers) and Immune Cell Function and Interaction (4 papers). Adrienne H. Long is often cited by papers focused on CAR-T cell therapy research (8 papers), Neuroblastoma Research and Treatments (4 papers) and Immune Cell Function and Interaction (4 papers). Adrienne H. Long collaborates with scholars based in United States, France and Canada. Adrienne H. Long's co-authors include Rimas J. Orentas, Crystal L. Mackall, Alec J. Walker, Terry J. Fry, Kelsey M. Wanhainen, Jillian Smith, Waleed Haso, Meera Murgai, M. Eric Kohler and Maria Ingaramo and has published in prestigious journals such as Nature Medicine, The Journal of Experimental Medicine and Blood.

In The Last Decade

Adrienne H. Long

12 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

2015 1.3k citations Adrienne H. Long, Waleed Haso et al. Nature Medicine profile →

Peers

Countries citing papers authored by Adrienne H. Long

Since Specialization

Citations

This map shows the geographic impact of Adrienne H. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrienne H. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrienne H. Long more than expected).

Fields of papers citing papers by Adrienne H. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrienne H. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrienne H. Long. The network helps show where Adrienne H. Long may publish in the future.

Co-authorship network of co-authors of Adrienne H. Long

This figure shows the co-authorship network connecting the top 25 collaborators of Adrienne H. Long. A scholar is included among the top collaborators of Adrienne H. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrienne H. Long. Adrienne H. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	COVID‐19 Vaccine Response in Pediatric Oncology Patients 2025 ·Pediatric Blood & Cancer ·(unknown), Yiwen Wang, Feifei Qin, Adrienne H. Long, Orly R. Klein, Catherine Aftandilian	0
2	Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients 2022 ·Frontiers in Oncology ·Agnes Reschke, Rebecca M. Richards, Stephanie M. Smith, Adrienne H. Long, Lianna J. Marks, Liora M. Schultz, (unknown), Catherine Aftandilian, Kara L. Davis, Tanja A. Grüber, Kathleen M. Sakamoto	2
3	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again 2022 ·American Society of Clinical Oncology Educational Book ·Adrienne H. Long, Daniel A. Morgenstern, Amaury Leruste, Franck Bourdeaut, Kara L. Davis	18
4	Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase 2017 ·Molecular Therapy ·Alec J. Walker, Robbie G. Majzner, Ling Zhang, Kelsey M. Wanhainen, Adrienne H. Long, Sang M. Nguyen, (unknown), Marc Vigny, Terry J. Fry, Rimas J. Orentas, Crystal L. Mackall	265
5	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas 2016 ·Cancer Immunology Research ·Adrienne H. Long, Steven L. Highfill, Yongzhi Cui, Jillian Smith, Alec J. Walker, Sneha Ramakrishna, (unknown), Susana Galli, Maria Tsokos, Rimas J. Orentas, Crystal L. Mackall	258
6	Abstract 2648: Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression 2016 ·Cancer Research ·Robbie G. Majzner, Alec J. Walker, Meera Murgai, Ling Zhang, Adrienne H. Long, Kelsey M. Wanhainen, Rimas J. Orentas, Crystal L. Mackall	2
7	Comparison against 186 canid whole-genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor 2015 ·Genome Research ·Brennan Decker, Brian W. Davis, Maud Rimbault, Adrienne H. Long, Eric Karlins, Vidhya Jagannathan, Rebecca Reiman, Heidi G. Parker, Cord Drögemüller, Jason J. Corneveaux, (unknown), Jeffery M. Trent, Tosso Leeb, Matthew J. Huentelman, Robert K. Wayne, Danielle M. Karyadi, Elaine A. Ostrander	43
8	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors breakdown → 2015 ·Nature Medicine ·Adrienne H. Long, Waleed Haso, Jack F. Shern, Kelsey M. Wanhainen, Meera Murgai, Maria Ingaramo, Jillian Smith, Alec J. Walker, M. Eric Kohler, (unknown), Rosandra N. Kaplan, George H. Patterson, Terry J. Fry, Rimas J. Orentas, Crystal L. Mackall	1252
9	Neutralization of murine myeloid suppressor cells enhances the efficacy of GD2-specific CAR T cells directed against human sarcoma in a xenograft model (VAC11P.1010) 2014 ·The Journal of Immunology ·Steven L. Highfill, (unknown), Adrienne H. Long, Yongzhi Cui, Rimas J. Orentas, Crystal L. Mackall	2
10	Lessons learned from a highly-active CD22-specific chimeric antigen receptor 2013 ·OncoImmunology ·Adrienne H. Long, Waleed Haso, Rimas J. Orentas	21
11	Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors 2013 ·Journal for ImmunoTherapy of Cancer ·Steven L. Highfill, Adrienne H. Long, Rimas J. Orentas, Crystal L. Mackall	3
12	Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells 2013 ·Blood ·Adrienne H. Long, Rimas J. Orentas, Crystal L. Mackall	2
13	A role for CD9 molecules in T cell activation. 1996 ·The Journal of Experimental Medicine ·Xuguang Tai, (unknown), Ryo Abe, Kazuhito Toyo‐oka, Clive R. Wood, Jennifer Morris, Adrienne H. Long, S Ono, Michiko Kobayashi, Takafumi Hamaoka, S Neben, H Fujiwara	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact